Skip to main content

PolyPid Ltd.

corporate_fare Company Profile

PolyPid Ltd.

PYPD·NASDAQ·Industrial Applications And Services·CIK 0001611842

PolyPid Ltd. is an innovative biopharmaceutical company focused on developing long-acting, controlled-release medicines that deliver therapy directly at the site of care to improve patient outcomes. The company's pipeline includes products for surgical care and metabolic diseases. Its lead product candidate is D-PLEX 100, which combines PolyPid's proprietary PLEX technology with doxycycline, an FDA-approved antibiotic. D-PLEX 100 is designed for direct administration into the surgical site during surgery, providing a prolonged and continuous release of high local concentrations of doxycycline for 30 days to prevent surgical site infections (SSIs). In June 2025, PolyPid Ltd. announced positive topline results from its pivotal SHIELD II Phase 3 study of D-PLEX 100. This study evaluated D-PLEX 100 for the prevention of SSIs in patients undergoing abdominal colorectal surgery with large incisions. D-PLEX 100 successfully met the primary and all key secondary endpoints of the study. SSIs occur in approximately 2% to 4% of all patients undergoing inpatient surgery and account for 20% of all healthcare-associated infections (HAIs) in the United States. The CDC estimates that SSIs result in up to $10 billion of additional hospital costs per year in the United States and are the costliest HAI type of event. The WHO and CDC have identified SSIs as a high priority unmet medical need.

PolyPid Ltd. (NASDAQ:PYPD) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 18 items for PYPD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for PYPD spans 6-K, 20-F.

Recent high-impact activity:

  • PolyPid Posts Q3 Loss of $0.24/Share; Cash to Fund Operations Into 2028 Ahead of Nov 28 PDUFA
  • PolyPid Posts Zero Revenue and Wider-Than-Expected Loss in Q3
  • PolyPid Adds Kynatrix-Based PD01b for Diabetic Foot Infections to Pipeline
  • EMA Validates PolyPid's D-PLEX100 Marketing Application, Starting Formal EU Review
  • PolyPid Regains European Rights to D-PLEX100 After ADVANZ PHARMA Deal Ends

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$34.17M
Diluted EPS
$2.09
Op. Cash Flow
-$27.88M
Free Cash Flow
-$28.09M
Operating Income
-$32.97M
Cash & Equivalents
$6.4M
Total Debt
$988K
Debt / Equity
0.09×
Shares Outstanding
18.2M sh
Source: 20-F · filed 2026-02-25 · accession 0001213900-26-020370

Short Interest & Short Volume

3.48 days to cover

FINRA reported short interest of 447,180 shares in PYPD as of the October 30, 2026 settlement, a 98.3% increase from the prior period — about 3.5 days to cover at its recent average daily volume. On November 20, 2026, 54.3% of PYPD volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)447,180 shares as of October 30, 2026
Change vs prior period▲ 98.3%
Days to cover3.48 at avg daily volume of 128,450
Daily short volume (FINRA facilities)54.3% of 186,275 shares on November 20, 2026
5-day average short volume33.7%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

PYPD files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with P →
$6.73 +9.91% today
52-week range · as of 2026-11-12 $3.5 – $7.15
Market cap
$129.29M
Volume
456.3K (2.2× avg)
3-mo avg 206.2K
Live data · 2026-11-22 07:48 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PYPD - Latest Insights

PYPD
Nov 12, 2026, 8:39 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $6.97
Real-time Price: $6.73 info
Change: -$0.2436 (-3%) info
Market Cap: $129.289M info
PYPD
Nov 11, 2026, 9:31 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $6.22
Real-time Price: $6.73 info
Change: +$0.5073 (+8%) info
Market Cap: $129.289M info
PYPD
Oct 28, 2026, 8:03 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.75
Real-time Price: $6.73 info
Change: +$0.9764 (+17%) info
Market Cap: $129.289M info
PYPD
Oct 01, 2026, 9:20 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.30
Real-time Price: $6.73 info
Change: +$1.43 (+27%) info
Market Cap: $129.289M info
PYPD
Oct 01, 2026, 8:56 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.27
Real-time Price: $6.73 info
Change: +$1.46 (+28%) info
Market Cap: $129.289M info
PYPD
Aug 12, 2026, 4:58 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.80
Real-time Price: $6.73 info
Change: +$1.93 (+40%) info
Market Cap: $129.289M info
PYPD
Aug 12, 2026, 7:35 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.35
Real-time Price: $6.73 info
Change: +$2.38 (+55%) info
Market Cap: $129.289M info
PYPD
Aug 12, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.46
Real-time Price: $6.73 info
Change: +$2.27 (+51%) info
Market Cap: $129.289M info
PYPD
Jul 29, 2026, 8:31 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $4.14
Real-time Price: $6.73 info
Change: +$2.59 (+62%) info
Market Cap: $129.289M info
PYPD
Jul 21, 2026, 8:49 AM EDT
Source: FinanceWire
Importance Score:
9
Price at Filing: $4.85
Real-time Price: $6.73 info
Change: +$1.88 (+39%) info
Market Cap: $129.289M info
PYPD
Jul 21, 2026, 7:35 AM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $4.76
Real-time Price: $6.73 info
Change: +$1.97 (+41%) info
Market Cap: $129.289M info
PYPD
Jun 10, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.51
Real-time Price: $6.73 info
Change: +$2.22 (+49%) info
Market Cap: $129.289M info
PYPD
Jun 01, 2026, 8:35 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.85
Real-time Price: $6.73 info
Change: +$1.88 (+39%) info
Market Cap: $129.289M info
PYPD
May 13, 2026, 7:35 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.28
Real-time Price: $6.73 info
Change: +$2.45 (+57%) info
Market Cap: $129.289M info
PYPD
Mar 31, 2026, 8:35 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.16
Real-time Price: $6.73 info
Change: +$2.57 (+62%) info
Market Cap: $129.289M info
PYPD
Mar 17, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.57
Real-time Price: $6.73 info
Change: +$2.15 (+47%) info
Market Cap: $129.289M info
PYPD
Feb 25, 2026, 4:01 PM EST
Filing Type: 20-F
Importance Score:
9
Price at Filing: $4.29
Real-time Price: $6.73 info
Change: +$2.44 (+57%) info
Market Cap: $129.289M info
PYPD
Feb 11, 2026, 7:35 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.82
Real-time Price: $6.73 info
Change: +$1.91 (+40%) info
Market Cap: $129.289M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets